GPX4 and breast carcinoma: Remarkably, we found that clinically utilized pan-HDAC inhibitors panobinostat and vorinostat synergize with GPX4 inhibitors to induce cell death in all tested lung, melanoma and breast cancer persister cell models but not in parental cells (Fig. 3, A to F and fig.